eXoZymes Q3 2026 Earnings Call - NCT Becomes Tyferyn as Curia Tech Transfer Begins, but Cash Runs to Early 2027
Summary
eXoZymes used its third-quarter update to rebrand its lead molecule NCT as Tyferyn and to lay out a regulatory and manufacturing path that now runs through contract manufacturer Curia Global. The company says its patent-pending process produced 535 grams of NCT at 99.6% purity in a 100-liter run, and it claims roughly tenfold productivity gains since then, though that figure is an internal estimate not yet proven at commercial scale. Management is targeting a single-dose human pharmacokinetic study in the first quarter of 2027 and a self-affirmed GRAS determination in the second quarter, while acknowledging that a proposed FDA rule on GRAS notification could alter the timeline. Commercialization hinges on a launch partner the company has not yet secured, and with $3.26 million in cash at quarter end, liquidity extends only into early 2027. The absence of a Q&A session, a consequence of the pending S-1 registration, left several open questions unanswered.
Key Takeaways
- eXoZymes rebranded its lead NCT product as Tyferyn and is registering the trademark, a signal that the company is moving from lab curiosity to consumer-facing brand.
- Curia Global was selected as commercial-scale manufacturing partner in September, with tech transfer beginning in Q4 across Curia's León, Spain fermentation site and Rozzano, Italy reaction and purification site, building toward larger-scale production in 2027.
- The January 2026 100-liter run at Cayman Chemical produced 535 grams of NCT at 99.6% purity with 99% feedstock conversion, the clearest process data point disclosed to date.
- Management claims roughly 67% more NCT per liter and a reaction rate about five times faster since the pilot, translating to an estimated tenfold productivity gain, but explicitly flags this as an internal estimate not demonstrated at commercial scale.
- The regulatory path rests on a self-affirmed GRAS determination targeted for Q2 2027 and a single-dose, IND-exempt human pharmacokinetic study targeted for Q1 2027, with claims limited to structure-function statements and no disease claims.
- A proposed FDA rule published August 11, 2026 would require notification of future GRAS determinations, and management concedes the regulatory path and timeline may change if it is finalized.
- Commercialization is planned through three channels, ingredient sales including offtake agreements, a direct-to-consumer brand potentially via joint venture, and marketing alliances, but no launch partner has been secured.
- The company remains asset-light by design, using CMO partners rather than building its own facilities, a capital discipline that matters given the balance sheet.
- Cash and equivalents stood at $3.26 million at September 30, sufficient only into the beginning of 2027, putting the S-1 offering squarely in the critical path.
- Q3 operating costs rose to $3.05 million from $2.52 million a year earlier, with R&D net of grants at $1.62 million and G&A at $1.43 million, reflecting increased program activity.
- The net loss of $2.24 million, or $0.24 per share, was lower than last year's $2.29 million only because of a $0.77 million non-cash gain from warrant liability remeasurement, while the operating loss actually widened.
- For the nine months, net loss was $7.49 million versus $6.5 million, and operating cash use was $5.39 million versus $4.53 million, a clear deterioration in cash burn.
- The pipeline carries gemstone code names: Amber (NCT) is in scale-up, Sapphire for joint comfort has begun scale-up, Amethyst for stress, focus and energy has completed proof of concept, and a women's health menopause program is under evaluation.
- More than 50 additional molecules have been screened and scored, but all pharmaceutical candidates, including NCT analogs and NIH grant-funded cannabinoid analogs, remain in discovery or lead optimization with no IND-enabling studies started.
- eXoZymes owns or exclusively licenses 14 patent families covering 29 issued patents, three allowed applications and 49 pending applications, though the core NCT process patent application is still pending and may not issue.
- The company was selected for the DOE Genesis Mission Grant to build AI-powered digital twins of cell-free biomanufacturing with Lawrence Berkeley National Laboratory, a non-dilutive funding win.
- No Q&A was held because of the pending S-1 registration statement, which has not yet become effective, leaving investors without answers on partnership timing, dilution and launch economics.
Full Transcript
Legal/Compliance Officer, eXoZymes: Before we begin, today’s remarks include forward-looking statements, including statements about our technology transfer to Curia, our GRAS determination, our planned human study, our commercialization plans for NCT, now called Tyferyn, our pipeline, and our financial condition. These statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially. Those risks are described in our annual report on Form 10-K for 2025, our quarterly report on Form 10-Q for the third quarter, which we filed on November 13, as well as our other SEC filings. We undertake no obligation to update these statements except as required by law. Statements about Tyferyn have not been evaluated by the FDA. Tyferyn is not intended to diagnose, treat, cure, or prevent any disease.
Michael Heltzen, CEO, eXoZymes: Good afternoon, and welcome to the eXoZymes third quarter 2026 investor update. I’m Michael Heltzen, CEO of eXoZymes. With me today are Dr. Tyler Korman, our Chief Scientific Officer, Damien Perriman, our Chief Commercial Officer, and Fouad Nawaz, our VP of Finance. As many of you know, we filed a registration statement on Form S-1 with the SEC. The registration statement has not yet become effective, and the securities it covers may not be sold, nor may offers to buy be accepted before it becomes effective. Nothing on today’s call is an offer to sell or a solicitation of an offer to buy any securities. Because we are in registration, we will not be discussing the proposed offering today, and for the same reason, we will not be holding a Q&A session on this call as we otherwise usually do. The registration statement is available on the SEC’s webpage.
With that, let me start with where we stand. Our mission is to unlock valuable molecules that only nature has been able to make until now for use in health, longevity, and other specialty applications. Many of these molecules are too rare in nature to extract and economically too hard to synthesize. Our platform uses exozymes, that is enzymes our scientists engineer with the help of AI and lab methods to run biochemistry outside of living cells and convert abundant feedstock into these valuable molecules at high purity. We apply the platform through a repeatable playbook with four stages. One, molecular prospecting, where we are screening potential ideas. Two, a molecular incubator for proof of concept. Three, a product accelerator that produces a tech transfer package. And four, commercialization that brings the product to market and first revenue.
For each molecule, we intend to pursue a fast-to-market route first, typically as a supplement ingredient, and then a pharmaceutical opportunity through engineered new-to-nature analogs that we would like to develop together with biotech and pharma partners. NCT Tyferyn is our lead program and the first we are taking through the full playbook. The main operational milestones of the period. In July, we were selected for the U.S. Department of Energy’s Genesis Mission Grant to build AI-powered digital twins of cell-free biomanufacturing with Lawrence Berkeley National Laboratory. In September, we selected Curia Global as our commercial-scale manufacturing partner for NCT, and the tech transfer to Curia began in this fourth quarter. We are in the process of registering the trademark Tyferyn for our NCT products and branding. Reminding you all that our strategy has five parts. First, bring NCT to market across different channels.
Create a pharmaceutical analog option for the NCT biosolution. Repeat the playbook with the next-in-line molecules, starting with the non-intoxicating cannabinoids. Stay capital-light by manufacturing through contract manufacturing organization partners rather than building our own facilities. Fifth, keep applying for non-dilutive funding. As always, please read our SEC filings to get a complete picture of eXoZymes and note that our November 2026 S-1 prospectus is not yet effective and will be updated soon. Please read the full and final version. Now, I’ll hand it over to Tyler for the science.
Dr. Tyler Korman, Chief Scientific Officer, eXoZymes: Thank you, Michael. Let me start with how our platform works. We make each enzyme in an industrial microbial host, such as E. coli or yeast, then run the enzymes together outside the cell, typically as a single one-pot cascade, and isolate the target molecule. Without a cell to keep alive, yields are not capped by growth or side products, and each pathway can be tuned for a single target. I began this work with co-founders Jim Bowie and Paul Opgenorth at UCLA over a decade ago, and since then, we have built a library of thousands of engineered exozymes. We believe our approach offers advantages in speed and cost and in access to rare molecules, although each still has to be proven at a commercial scale and over time. Now to NCT, which is now called Tyferyn.
NCT is a rare plant compound found in black peppercorns and other plants at less than 15 parts per million. Published research has identified NCT as the first potent selective activator of HNF4-alpha, a nuclear receptor that regulates genes controlling mitochondrial function, fat metabolism, and gut barrier integrity, and a target with no approved therapy. So what does our process data show for NCT? In January 2026, our independent partner, Cayman Chemical, ran our patent-pending NCT process in a 100-liter reactor. That run produced 535 grams of NCT at 99.6% purity and converted 99% of the feedstock into product. Since that pilot run, we’ve optimized the process to produce approximately 67% more NCT per liter of reactor volume, with a reaction rate approximately five times faster. We’ve also moved it onto unit operations used by commercial manufacturers.
We estimate these changes will increase productivity approximately tenfold compared with the pilot process. But I want to be precise here. That is an internal estimate, and it has not been demonstrated at commercial scale. Next, let’s look at the published research. A published third-party study in diet-induced obese mice found NCT-treated mice gained 30%-40% less weight than untreated mice on the same diet at equal caloric intake. Two small, short, randomized placebo-controlled human studies by third parties used a blend of NCT and a related molecule, NFT, and met their primary endpoints. To be clear, we did not conduct these studies. They were performed by others and used a blend of NCT and a related molecule, NFT, rather than our pure NCT, and their results may not be predictive of results with our product.
Separately, a published 90-day tox study supports an estimated safe intake of approximately 992 milligrams per day for a 70-kilogram adult, which we intend to use in our GRAS determination. Turning now to our pipeline, our supplement programs carry gemstone code names. Amber, based on NCT, has completed discovery and proof of concept and is now in scale-up, with GRAS work and clinical studies planned in parallel. Sapphire, for joint comfort, has completed proof of concept and begun scale-up. Amethyst, for mental stress, focus, and energy, has completed proof of concept. We are also evaluating a women’s health program focused on menopause support and have screened and scored more than 50 additional molecules with potential to support human health. On the pharmaceutical side, our candidates are engineered analogs, including NCT analogs and NIH grant-funded cannabinoid analogs.
All are in discovery or lead optimization, and none has begun IND-enabling studies or clinical trials. Finally, with regard to intellectual property, as of November 11, 2026, we owned or exclusively licensed 14 patent families, comprising 29 issued patents, three allowed applications, and 49 pending applications in the U.S., Europe, and 13 other countries and territories. Our NCT process patent application is pending and may not issue. With that, I will hand it over to Damien to walk through manufacturing and commercialization.
Damien Perriman, Chief Commercial Officer, eXoZymes: Thank you, Tyler. Today, I am going to walk you through a manufacturing, regulatory, and commercialization update. In September, we selected Curia Global as our commercial-scale manufacturing partner for Tyferyn. Curia will perform the full process, enzyme fermentation at its facility in León, Spain, and the cell-free reaction and purification at its facility in Rozzano, Italy. Technology transfer began in the fourth quarter, building towards larger-scale production in 2027. We do not plan to build our own manufacturing facilities, keeping this an asset-light commercialization journey. On the regulatory path, we intend to market Tyferyn as a dietary supplement ingredient. Claims will be limited to structure-function statements with no disease claims at any stage.
The path has three elements: a safety evaluation by an independent expert panel to support a self-affirmed GRAS determination for market entry, targeted for the second quarter of 2027; a single-dose, IND-exempt human pharmacokinetic study in healthy adults, targeted for the first quarter of 2027. This will confirm absorption and set the dose level for future studies. Formulation work and targeted studies to substantiate additional structure-function claims have already happened and will be ongoing. One development we are watching closely, the FDA published a proposed rule on August 11, 2026, that would require FDA notification of future GRAS determinations. If it is finalized, our regulatory path and timeline may change. On the commercialization update, we intend to commercialize Tyferyn through one or more of three channels. Firstly, ingredient sales to supplement brands and formulators, including through offtake agreements.
Secondly, our own direct-to-consumer brand, potentially through a joint venture or other co-owned structure. Thirdly, marketing alliances across the online and, once sales velocity is established, retail channels. We plan to fully own the Tyferyn technology through the journey of GRAS determination and the Curia technology transfer. At the same time or after those milestones, either partner or take Tyferyn to market ourselves. The structure of any partnership or spin-out has not yet been determined. To be clear, the NCT launch timeline depends on Curia completing our scale-up and technology transfer, on our securing a marketing launch partner, which we have not yet done, and on regulatory requirements in the markets where NCT will be sold. Thank you. Fouad will take you through the financials.
Fouad Nawaz, VP of Finance, eXoZymes: Thank you, Damien. Good afternoon, everyone. I will provide a summary of our financial results that were reported in our unaudited third quarter 10-Q, which was filed on November 13th. Our total operating costs for the third quarter were $3.05 million, compared with $2.52 million in the third quarter of 2025. Research and development costs net of grant reimbursements were $1.62 million versus $1.22 million, reflecting increased program activity. General and administrative costs were $1.43 million versus $1.31 million in 2025. The net loss for the quarter was $2.24 million, or $0.24 per share, compared with $2.29 million, or $0.27 per share a year ago. I want to be clear that the net loss is lower than last year only because of non-cash gain of $0.77 million from the change in fair value of warrant liabilities related to our June offering. Our overall operating loss did increase.
For the nine months, the net loss was $7.49 million compared with $6.5 million in 2025, and cash used in our operating activities was $5.39 million compared with $4.53 million in the same period of 2025. We ended September with $3.26 million in cash and cash equivalents, which will provide us sufficient liquidity to support ongoing operations and key initiatives into the beginning of 2027. We continue to be disciplined in our spending approach and continue to ensure capital is allocated efficiently to maximize shareholder value. Additionally, we continue to explore non-dilutive funding opportunities, strategic partnerships, and potential government grants to further strengthen our financial position. With that, I will pass the call back to Michael.
Michael Heltzen, CEO, eXoZymes: Thank you, team. To summarize the quarter, we selected Curia as our commercial scale manufacturing partner and began the tech transfer. We were selected for the DOE Genesis Mission, and we continue to advance the NCT regulatory work with a single-dose human PK study targeted to be communicated in the first quarter of 2027, and a GRAS determination targeted for the second quarter of 2027. Those targets depend on factors we have described today, and we will keep reporting progress as it happens. That concludes today’s update. Thank you very much for your support and continued interest.